SCHEMBL24993465

SCHEMBL24993465

CN(C)Cc1nc(NC(=O)OC(C)(C)C)ccc1C1=CCCC1

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.34
DYRK1A Q13627 1/20 0.34
HDAC1 Q13547 3/20 0.33
HDAC2 Q92769 3/20 0.33
AKT1 P31749 2/20 0.33
AAK1 Q2M2I8 1/20 0.33
HDAC3 O15379 1/20 0.33
PSMB5 P28074 1/20 0.33
MAPKAPK2 P49137 4/20 0.32
NAMPT P43490 1/20 0.32
SCN9A Q15858 1/20 0.32
CYP17A1 P05093 2/20 0.31
ATR Q13535 1/20 0.31
CTSL P07711 1/20 0.30
CTSB P07858 1/20 0.30
CTSS P25774 1/20 0.30
GRM2 Q14416 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30865560 1.00 GSK3B (0.34) GSK3BDYRK1AHDAC1HDAC2AKT1
SCHEMBL23104424 0.85 PIK3CA (0.36) GSK3BDYRK1AAAK1MAPKAPK2CTSS
SCHEMBL30630161 0.85 PIK3CA (0.36) GSK3BDYRK1AAAK1MAPKAPK2CTSS
SCHEMBL30173047 0.83 AAK1 (0.35) GSK3BDYRK1AAKT1AAK1MAPKAPK2
SCHEMBL24992624 0.83 AAK1 (0.35) GSK3BDYRK1AAKT1AAK1MAPKAPK2
SCHEMBL23104024 0.82 GSK3B (0.34) GSK3BDYRK1AAKT1AAK1MAPKAPK2
SCHEMBL29736433 0.82 GSK3B (0.34) GSK3BDYRK1AAKT1AAK1MAPKAPK2
SCHEMBL23103813 0.79 GSK3B (0.37) GSK3BDYRK1AHDAC1HDAC2AKT1
SCHEMBL29814648 0.79 GSK3B (0.37) GSK3BDYRK1AHDAC1HDAC2AKT1
SCHEMBL24993471 0.75 MAPKAPK2 (0.36) GSK3BDYRK1AMAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250011331-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2025-01-09 US disclosed
EP-4380565-A1 HPK1 ANTAGONISTS AND USES THEREOF Nimbus Saturn, Inc. (US) 2024-06-12 EP disclosed
CN-117915912-A HPK1 antagonists and uses thereof 林伯士萨顿公司 2024-04-19 CN disclosed
WO-2023015199-A1 HPK1 ANTAGONISTS AND USES THEREOF Nimbus Saturn, Inc. (US) 2023-02-09 WO disclosed
WO-2023015199-A1 HPK1 ANTAGONISTS AND USES THEREOF Nimbus Saturn, Inc. (US) 2023-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011331-A1 HPK1 ANTAGONISTS AND USES THEREOF PDXK, HIPK1, PCK1 GSK3B 537/4885DYRK1A 860/4885HDAC1 1837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.